Primary IgA Nephropathy Clinical Trial
Official title:
Treatment of Shentong Granules Plus Prednisone on Patients With Severe IgA Nephropathy(Ying-deficiency of the Liver and Kidney Pattern): a Randomized, Double-blind,Placebo-controlled Multicentre Clinical Trial
The present study was designed to identify the efficacy and safety of Integrative Medicine by joint oral steroid medicine on liver-kidney yin deficiency, severe IgA nephropathy. Furthermore, search for potential diagnostic predictor in IgA Nephropathy by Proteomics and Metabolomics.
The present study was designed to identify the efficacy and safety of Integrative Medicine by joint oral steroid medicine on liver-kidney yin deficiency, severe IgA nephropathy. Furthermore, search for potential diagnostic predictor in IgA Nephropathy by Proteomics and Metabolomics. Combined with TCM Syndrome research, the investigators will clarify targets or mechanisms of herbal treatment. Eventually, to form a more clinically appropriate standardized combination treatment of severe IgA nephropathy. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03643965 -
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
|
Phase 3 | |
| Recruiting |
NCT04557462 -
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
|
Phase 3 | |
| Active, not recruiting |
NCT04541043 -
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
|
Phase 3 | |
| Recruiting |
NCT05847920 -
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
|
Phase 2 | |
| Recruiting |
NCT02765594 -
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
|
Phase 4 | |
| Completed |
NCT04887532 -
A Trial of HR19042 Capsule in Healthy Chinese Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06137768 -
A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
|
Phase 2 | |
| Completed |
NCT02351752 -
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
|
Phase 4 | |
| Active, not recruiting |
NCT04014335 -
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
|
Phase 2 | |
| Completed |
NCT01738035 -
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
|
Phase 2 | |
| Recruiting |
NCT05797610 -
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
|
Phase 3 |